title: Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat.
abstract: Most antidepressants produce changes in monoamine receptors in brain after chronic administration in animals. The most commonly described alterations are a decreased density and function of beta-adrenergic receptors and have been postulated to be the mechanisms by which antidepressants exert their therapeutic effect. Milnacipran (previous name midalcipran) is a new, clinically-effective antidepressant, which inhibits the uptake of both serotonin and noradrenaline but has no affinity for any pre- or postsynaptic receptor studied. When given either orally at 7.5 mg/kg twice daily for 3 days, at 30 mg/kg once daily for 3 weeks, by osmotic mini-pump at 30 mg/kg/day for 27 days, or in drinking water at approximately 15 mg/kg/day for 6 weeks and after a washout period of 24 hr, milnacipran produced no down-regulation of beta-adrenoceptors. In addition, there were no alterations of alpha 1- or alpha 2-adrenoceptors, 5-HT1, 5-HT2 receptors or benzodiazepine binding sites. Moreover, uptake and accumulation of serotonin and noradrenaline were unmodified. In addition, the potency for milnacipran to inhibit monoamine uptake in vitro in the cortex was not altered in treated rats, compared to control animals. Thus, in spite of its action on both the uptake of serotonin and noradrenaline, milnacipran appears to be without long-term action on beta-adrenoceptors or the other receptors studied, suggesting that, at least for this antidepressant, these modifications are not essential for clinical activity.
authors.affiliation: Centre de Recherche Pierre Fabre, Castres, France.
authors.forename: M B
authors.initials: MB
authors.lastname: Assie
authors.forename: M
authors.initials: M
authors.lastname: Charveron
authors.forename: C
authors.initials: C
authors.lastname: Palmier
authors.forename: C
authors.initials: C
authors.lastname: Puozzo
authors.forename: C
authors.initials: C
authors.lastname: Moret
authors.forename: M
authors.initials: M
authors.lastname: Briley
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003521:Cyclopropanes / Q000008:administration & dosage / Q000494:pharmacology*; D015536:Down-Regulation; D004334:Drug Administration Schedule; D007700:Kinetics; D008297:Male; D000078764:Milnacipran; D009638:Norepinephrine / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000378:metabolism*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000378:metabolism*; D011963:Receptors, GABA-A / Q000187:drug effects / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism*
chemical_list: D000928:Antidepressive Agents; D003521:Cyclopropanes; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D011963:Receptors, GABA-A; D011985:Receptors, Serotonin; D012701:Serotonin; D000078764:Milnacipran; D009638:Norepinephrine